A new class of 5-fluoro-2′-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: Synthesis, reactivity, and tumor-cell-selective cytotoxicity

Pharmaceutical Research

Volumn 22, Issue 3, 2005, Pages 381-389

  Zhang, Zhouen ^a   Hatta, Hiroshi ^a   Tanabe, Kazuhito ^a   Nishimoto, Sei Ichi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

5 fluoro 2 deoxyuridine; Anticancer prodrug; Cytotoxicity; Hydrolysis; Tumor homing peptide

Indexed keywords

BUFFER; CYCLOPEPTIDE; CYSTEINYLASPARAGINYLGLYCYLARGINYLCYSTEINE; ESTER; FLOXURIDINE DERIVATIVE; GLUTARIC ACID; MICROSOMAL AMINOPEPTIDASE; PHOSPHATE; PRODRUG; SUCCINIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CELL LYSATE; CELL STRAIN; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG RELEASE; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; SERUM; SOLID; STRUCTURE ANALYSIS; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ESTERS; FLOXURIDINE; HUMANS; PEPTIDES, CYCLIC; PRODRUGS;

EID: 17644384819     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-1875-x     Document Type: Article

References (38)

1. E. Chu, A. Mota, and M. C. Fogarasi. Pharmacology of cancer chemotherapy. In V. T. DeVita, S. Hellman and S. A. Rosenberg (eds.). Cancer Principles & Practice of Oncology, 6th ed., Vol. 1. Lippincott Williams & Wilkins: Philadelphia, 2001, pp. 388-415.
2. C. E. Myers. The pharmacology of the fluoropyrimidines. Pharmacol. Rev. 33:1-15 (1981).
3. J. A. van Laar, Y. M. Rustum, S. P. Ackland, C. J. van Groeningen. and G. J. Peters. Comparison of 5-fluoro-2′-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. Eur. J. Cancer 34:296-306 (1998).
4. S. Fukushima, T. Kawaguchi M, Nishida, K. Juni, Y. Yamshita, M. Takahashi, and M. Nakano. Selective anticancer effects of 3′,5′- dioctanoyl-5-fluoro-2′-deoxyuridine, a lipophilic prodrug of 5-fluoro-2′-deoxyuridine, dissolved in an oily lymphographic agent on hepatic cancer of rabbits bearing VX-2 tumor. Cancer Res. 47:1930-1934 (1987).
5. B. S. Vig, P. J. Lorenzi, S. Mittal, C. P. Landowski, H. Shin, H. Mosberg, J. M. Hilfinger, and G. L. Amidon. Amino acid ester prodrugs of fluorodeoxyuridine: synthesis and effects of structure, stereochemistry, and site of esterification on rate of hydrolysis. Pharm. Res. 20:1381-1388 (2003).
6. Z. Xia, L. I. Wiebe, G. G. Miller, and E. E. Knaus. Synthesis and biological evaluation of butanoate, retinoate, and bis(2,2.2-trichloroethyl) phosphate derivatives of 5-fluoro-2′-deoxyuridine and 2′,5-difluoro- 2′-deoxyuridine as potential dual action anticancer prodrugs. Arch. Pharm. (Weiheim) 332:286-294 (1999).
7. K. Tanabe, Y. Mimasu, A. Eto, Y. Tachi, S. Sakakibara, M. Mori, H. Hatta, and S. Nishimoto. One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs. Bioorg. Med. Chem. 11:4551-4556 (2003).
8. Y. Shibamoto, Y. Tachi, K. Tanabe, H. Hatta, and S. Nishimoto. In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2′- deoxyuridine activated by hypoxic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 58:397-402 (2004).
9. Y. Wei, Y. Yan, D. Pei, and B. Gong. A photoactivated prodrug. Bioorg. Med. Chem. Lett. 8:2419-2422 (1998).
10. G. A. Koning, J. A. Kamps, and G. L. Scherphof. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes. Cancer Detect. Prev. 26:299-307 (2002).
11. G. A. Koning, A. Gorter, G. L. Scherphof, and J. A. Kamps. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine- dipalmitate on colon cancer cells. Br. J. Cancer 80:1718-1725 (1999).
12. A. Goerlach, K. G. Krauer, I. F. McKenzie, and G. A. Pietersz. In vitro antitumor activity of 2′-deoxy-5-fluorouridine-monoclonal antibody conjugates. Bioconjug. Chem. 2:96-101 (1991).
13. D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmaco. Rev. 51:691-743 (1999).
14. S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, and R. K. Jain. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA 95:4607-4612 (1998).
15. I. Brigger, C. Dubernet, and P. Couvreur. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54:631-651 (2002).
16. P. D. Senter and C. J. Springer. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Deliv. Rev. 53:247-264 (2001).
17. E. C. Ko, X. Wang, and S. Ferrone. Immunotherapy of malignant diseases. Challenges and strategies. Int. Arch. Allergy Immunol. 132:294-309 (2003).
18. E. Ruoslahti. Specialization of tumor vasculature. Nat. Rev. Cancer 2:83-90 (2002).
19. P. Alessi, C. Ebbinghaus, and D. Neri. Molecular targeting of angiogenesis. Biochim. Biophys. Acta 1654:39-49 (2004).
20. E. Ruoslahti and D. Rajotte. An address system in the vasculature of normal tissues and tumors. Annu. Rev. Immunol. 18:813-827 (2000).
21. R. Pasqualini and E. Ruoslahti. Organ targeting in vivo using phage display peptide libraries. Nature 380:364-366 (1996).
22. K. Porkka, P. Laakkonen, J. A. Hoffman, M. Bernasconi, and E. Ruoslahti. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA 99:7444-7449 (2002).
23. L. A. Landon and S. L. Deutscher. Combinatorial discovery of tumor targeting peptides using phage display. J. Cell. Biochem. 90:509-517 (2003).
24. W. Arap, R. Pasqualini, and E. Ruoslahti. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380 (1998).
25. M. Trepel, W. Arap, and R. Pasqualini. In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr. Opin. Chem. Biol. 6:399-404 (2002).
26. R. Pasqualini, E. Koivunen, R. Kain, J. Lahdenranta, M. Sakamoto, A. Stryhn, R. A. Ashmun, L. H. Shapiro, W. Arap, and E. Ruoslahti. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60:722-727 (2000).
27. F. Curnis, G. Arrigoni, A. Sacchi, L. Fischetti, W. Arap, R. Pasqualini, and A. Corti. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62:867-874 (2002).
28. H. Tamamura, A. Omagari, K. Hiramatsu, T. Kanamoto, K. Gotoh, K. Kanbara, N. Yamamoto, H. Nakashima, A. Otaka, and N. Fuji. Synthesis and evaluation of biofunctional anti-HIV agents based on specific CXCR4 antagonist-AZT conjugation. Bioorg. Med. Chem. 9:2179-2187 (2001).
29. A. Nagy, A. Polnowski, and A. V. Schally. Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies. Proc. Natl. Acad. Sci. USA 97:829-834 (2000).
30. H. Tamamura, T. Ishihara, H. Oyake, M. Imai, A. Otaka, T. Ibuka, R. Arakaki, H. Nakashima, T. Murakami, M. Waki, A. Matsumoto, N. Yamamoto, and N. Fujii. Convenient one-pot synthesis of cystine-containing peptides using the trimethylsilyl chloride-dimethyl sulfoxide/trifluoroacetic acid system and its application to the synthesis of bifunctional anti-HIV compounds. J. Chem. Soc., Perkin Trans. 1 1:495-500 (1998).
31. T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63 (1983).
32. Y. Shibamoto, Y. Mimasu, Y. Tachi, H. Hatta, and S. Nishimoto. Comparison of 5-fluorouracil and 5-fluoro-2′-deoxyuridine as an effector in radiation-activated prodrugs. J. Chemother. 14:390-396 (2002).
33. Y. van Hensbergen, H. J. Broxterman, Y. W. Elderkamp, J. Lankelma, J. C. Beers, M. Heijn, E. Boven, K. Hoekman, and H. M. Pinedo. A doxorubicin-CNGRC- peptide conjugate with prodrug properties. Biochem. Pharmacol. 63:897-908 (2002).
34. J. S. Shim, J. H. Kim, H. Y. Cho, Y. N. Yum, S. H. Kim, H. J. Park, B. S. Shim, S. H. Choi, and H. J. Kwon. Irreversible inhibition of CD13/aminopeptidase N by the antiangiogenic agent curcumin. Chem. Biol. 10:695-704 (2003).
35. D. Riemann, A. Kehlen, K. Thiele, M. Löhn, and J. Langner. Induction of aminopeptidase N/CD13 on human lymphocytes after adhesion to fibroblast-like synoviocytes, endothelial cells, epithelial cells, and monocytes/macrophages. J. Immunol. 158:3425-3432 (1997).
36. F. Curnis, A. Sacchi, L. Borgna, F. Magni, A. Gasparri, and A. Corti. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol 18:1185-1190 (2000).
37. W. Arap, M. G. Kolonin, M. Trepel, J. Lahdenranta, M. Cardo-Vila, R. J. Giordano, P. J. Mintz, P. U. Ardelt, V. J. Yao, C. I. Vidal, L. Chen, A. Flamm, H. Valtanen, L. M. Weavind, M. E. Hicks, R. E. Pollock, G. H. Botz, C. D. Bucana, E. Koivunen, D. Cahill, P. Troncoso, K. A. Baggerly, R. D. Pentz, K. A. Do, C. J. Logothetis, and R. Pasqualini. Steps toward mapping the human vasculature by phage display. Nat. Med. 8:121-127 (2002).
38. F. Pastorino, C. Brignole, D. Marimpietri, M. Cilli, C. Gambini, D. Ribatti, R. Longhi, T. M. Allen, A. Corti, and M. Ponzoni. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63:7400-7409 (2003).